Cyclacel Pharmaceuticals (CYCC)
(Delayed Data from NSDQ)
$1.02 USD
-0.01 (-0.97%)
Updated Sep 17, 2024 03:12 PM ET
After-Market: $1.01 -0.01 (-0.98%) 7:58 PM ET
2-Buy of 5 2
F Value A Growth B Momentum C VGM
Cyclacel Pharmaceuticals, Inc. (CYCC) Price Targets
Average Price Target | Highest Price Target | Lowest Price Target | Upside to Average Price Target |
---|---|---|---|
$11.00 | $11.00 | $11.00 | 967.96% |
Price Target
Only one analyst offered a short-term price target of $11.00 for Cyclacel Pharmaceuticals, Inc. This represents an increase of 967.96% from the last closing price of $1.03.
Analyst Price Targets (1 )
Broker Rating
Only one brokerage firm provided a Strong Buy-equivalent recommendation for Cyclacel Pharmaceuticals, Inc. This translates to an average brokerage recommendation (ABR) of 1.00 on a scale of 1 to 5 (Strong Buy to Strong Sell). ABR is the calculated average of actual recommendations (Buy, Hold, Sell etc.) made by brokerage firms.
The current ABR compares to an ABR of 1.00 a month ago based on just one Strong Buy recommendation.
Broker Rating Breakdown
Brokerage Recommendations
Today | 1 Week Ago | 1 Month Ago | 2 Months Ago | 3 Months Ago | |
---|---|---|---|---|---|
Strong Buy | 1 | 1 | 1 | 2 | 2 |
Buy | 0 | 0 | 0 | 0 | 0 |
Hold | 0 | 0 | 0 | 0 | 0 |
Sell | 0 | 0 | 0 | 0 | 0 |
Strong Sell | 0 | 0 | 0 | 0 | 0 |
ABR | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Analyst Upgrades/Downgrades
Date | Brokerage Firm | Analyst | Previous | Current |
---|---|---|---|---|
8/14/2024 | Roth Capital Partners | Jonathan Aschoff | Strong Buy | Strong Buy |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Average Brokerage Rating
Current ABR | 1.00 |
ABR (Last week) | 1.00 |
# of Recs in ABR | 1 |
Average Target Price | $11.00 |
LT Growth Rate | NA |
Industry | Medical - Biomedical and Genetics |
Industry Rank by ABR | 79 of 253 |
Current Quarter EPS Est: | -0.54 |
CYCC FAQs
Cyclacel Pharmaceuticals, Inc. (CYCC) currently has an average brokerage recommendation (ABR) of 1.00 on a scale of 1 to 5 (Strong Buy to Strong Sell), calculated based on the actual recommendations (Buy, Hold, Sell etc.) made by 1 brokerage firms.
The average price target for Cyclacel Pharmaceuticals, Inc. (CYCC) is $11.00. The current on short-term price targets is based on 1 reports.
The forecasts for Cyclacel Pharmaceuticals, Inc. (CYCC) range from a low of $11 to a high of $11. The average price target represents a increase of $978.43 from the last closing price of $1.02.
The current UPSIDE for Cyclacel Pharmaceuticals, Inc. (CYCC) is 978.43%
Only one analyst offered a short-term price target of $11.00 for Cyclacel Pharmaceuticals, Inc. This represents an increase of 967.96% from the last closing price of $1.03.